News | September 09, 2025
Congruence gets $32 million financing to advance genetic obesity candidate drug
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Subscribe To Our Newsletter & Stay Updated
